Adrafinil is a synthetic wakefulness-promoting compound that the body converts into modafinil, a well-known prescription stimulant. Discovered in the late 1970s by Lafon Laboratories in France, it was originally developed to treat narcolepsy and age-related neurological symptoms in elderly patients. It was marketed under the brand name Olmifon. Unlike modafinil, adrafinil is not FDA-approved in the United States, which places it in a regulatory gray area that has made it popular in nootropic and cognitive-enhancement communities.
How Adrafinil Works in the Body
Adrafinil is a prodrug, meaning it has little direct activity on its own. After you swallow it, your liver metabolizes it into modafinil, which is the compound that actually promotes wakefulness. This conversion step is why adrafinil takes longer to kick in and requires a higher dose to achieve effects comparable to modafinil. Taken on an empty stomach, adrafinil typically begins working within 45 minutes to an hour.
Once converted, modafinil influences several chemical messenger systems in the brain simultaneously. It weakly blocks the reuptake of dopamine by binding to the dopamine transporter, keeping more dopamine active in the spaces between neurons. It also increases levels of norepinephrine, histamine, and serotonin. Researchers have not been able to pin down a single site of action, which makes it different from traditional stimulants like amphetamines that work through a more focused mechanism.
One notable effect involves the brain’s sleep-promoting center. Modafinil appears to suppress this region through norepinephrine signaling, essentially quieting the part of the brain that makes you drowsy. It also activates orexin neurons, the same cells that are dysfunctional in people with narcolepsy. At the same time, it reduces levels of GABA, the brain’s primary calming chemical, partly through a serotonin-mediated pathway. The net result is a state of sustained alertness without the jitteriness or crash commonly associated with caffeine or amphetamines.
Adrafinil vs. Modafinil
The most common question people have is why anyone would take adrafinil instead of modafinil. The answer is mostly about access. Modafinil is a prescription medication in the US, UK, and most other countries. Adrafinil, because it was never FDA-approved, has historically been sold as an unregulated supplement in several markets.
From a pharmacological standpoint, modafinil is the superior compound. Lafon Laboratories discovered during metabolism studies that adrafinil was primarily inactivated by the liver, with only a fraction being converted into the active metabolite modafinil. This led the company to develop modafinil directly as a more potent and longer-lasting drug. In practical terms, this means you need roughly three times as much adrafinil by weight to achieve effects similar to a standard modafinil dose. Once modafinil is active in your system, it reaches peak blood levels in 2 to 4 hours and has an effective half-life of about 15 hours after repeated dosing. One of its metabolites, modafinil sulfone, has a half-life of 40 hours and accumulates with regular use.
The Liver Concern
Because adrafinil must pass through the liver to become modafinil, it places additional metabolic demand on this organ compared to taking modafinil directly. The conversion process generates byproducts that the liver must clear, and prolonged or heavy use has raised concerns about elevated liver enzymes. These enzymes, commonly measured as ALT and AST, are markers of liver cell stress. Normal levels sit below 45 IU/L, and persistent elevations above twice that threshold generally warrant further evaluation.
No large-scale clinical trials have specifically quantified adrafinil’s liver risk, which is itself part of the problem. The drug was withdrawn from the French market in 2011, and without regulatory oversight in most countries, safety monitoring has been minimal. People who use adrafinil regularly sometimes get periodic liver function tests to check for enzyme elevations, though the lack of formal dosing guidelines makes it difficult to define what “safe” long-term use looks like.
Side Effects
Because adrafinil converts to modafinil, the side effect profiles overlap significantly. The most commonly reported effects include headache, nausea, dizziness, insomnia, and anxiety. These tend to be mild and dose-dependent.
Skin reactions deserve special attention. Modafinil has been associated with serious dermatological events including Stevens-Johnson syndrome, toxic epidermal necrolysis, and a condition called DRESS (a severe rash with organ involvement). In clinical studies of adult patients, these serious reactions were extremely rare: zero cases among 4,264 patients in one large dataset. However, pediatric patients showed a higher incidence, with 13 cases of skin adverse reactions, including serious ones, among 1,585 patients aged 17 and younger. Any unexplained rash that develops after starting adrafinil should be taken seriously.
Other reported skin-related effects include hives, excessive sweating, and itching. One published case described a patient who developed an unusual acne-like dermatitis with itchy nodules under the skin after two years of regular modafinil use, illustrating that reactions can emerge well after the initial period of use.
Legal and Regulatory Status
Adrafinil occupies an unusual legal position. In the United States, it is not a scheduled controlled substance, but it also has no FDA approval for any medical use. This means it can be sold as a research chemical or supplement without a prescription in some contexts, though its regulatory status can shift. In contrast, modafinil is a Schedule IV controlled substance in the US, requiring a prescription.
In competitive sports, adrafinil is clearly prohibited. The World Anti-Doping Agency (WADA) bans it under its S0 category, which covers non-approved substances. This category prohibits any pharmacological substance that lacks current approval by a governmental health authority for human therapeutic use. Since adrafinil has no active regulatory approval anywhere, it falls squarely within this classification and is banned at all times, both in and out of competition.
Who Uses Adrafinil and Why
The typical adrafinil user is not someone with narcolepsy. Most people who seek it out are looking for cognitive enhancement: better focus during long work sessions, reduced fatigue during shift work, or a general boost in mental sharpness. It gained popularity in online nootropic communities precisely because it offered a legal pathway to modafinil-like effects without a prescription.
This accessibility comes with trade-offs. The extra liver processing means a slower onset, lower potency per milligram, and additional organ strain compared to modafinil itself. The lack of pharmaceutical-grade manufacturing standards for most commercially available adrafinil also introduces quality control concerns. Products sold online may vary in purity, and contamination or inaccurate dosing is a real possibility when buying from unregulated sources. For people who have a legitimate medical need for wakefulness promotion, modafinil prescribed by a physician remains the more effective and better-studied option.